Grifols shares surge on US biopharma biz IPO plan

Grifols

25/03/2026 08:43

** Shares of Grifols GRLS.MC rise nearly 9% to top of pan-European STOXX .STOXX index after the Spanish drugmaker said it approved a U.S. initial public offering of its U.S. biopharma business

** "The transaction would enable Grifols to crystallise value in its core business (Biopharma accounts for 86% of sales and recorded LfL growth of +8.4% in 2025) and in its most significant market", Banco Sabadell says

** The brokerage, which estimates that U.S accounts for around 55% of Grifols total sales, adds that the funds acquired in this transaction would also accelerate the company's debt reduction

** Grifols shares enjoy their best day since end-July

 (Reporting by Tiago Brandao)

 ((Tiago.Brandao@thomsonreuters.com;))